Cargando…
Efficacy of palifermin (keratinocyte growth factor-1) in the amelioration of oral mucositis
PURPOSE: Oral mucositis is a significant toxicity of cytotoxic chemo- and radiation-therapy used to treat cancer. Palifermin is the first pharmaceutical/biological agent approved for the intervention of oral mucositis. The major objective of this review is to evaluate the evidence supporting the use...
Autor principal: | Sonis, Stephen T |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2010
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2899789/ https://www.ncbi.nlm.nih.gov/pubmed/20694076 |
Ejemplares similares
-
Clinical applications of palifermin: amelioration of oral mucositis and other potential indications
por: Vadhan-Raj, Saroj, et al.
Publicado: (2013) -
Efficacy of keratinocyte growth factor (palifermin) for the treatment of caustic esophageal burns
por: NUMANOĞLU, KEMAL VARIM, et al.
Publicado: (2014) -
Palifermin for management of treatment-induced oral mucositis in cancer patients
por: Barasch, Andrei, et al.
Publicado: (2009) -
Efficacy of Palifermin in the Hematopoietic Stem Cell Transplant Setting
por: Panjwani, Muneera
Publicado: (2013) -
Emerging new clinical applications for palifermin: beyond its use in oral mucositis and graft versus host disease
por: Kapoor, Shailendra
Publicado: (2012)